Hubei Jumpcan Pharmaceutical Co., Ltd.
600566
주식 순위
#4335
Hubei Jumpcan Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the... Hubei Jumpcan Pharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the full spectrum of pharmaceutical operations, encompassing research, development, production, and marketing. The company's product lines include both traditional Chinese and Western medicines, as well as daily-use chemical products incorporating traditional Chinese medicine, and health supplements rooted in Chinese medical practices. Their diverse range of Chinese and Western pharmaceuticals addresses a wide array of therapeutic areas, such as pediatric care, women's health, respiratory conditions, digestive disorders, and geriatric medicine. Additionally, their development pipeline covers treatments for detoxification, nervous system ailments, anti-infective agents, cardiovascular issues, pain relief, nutritional deficiencies, musculoskeletal problems, and blood clotting management. Beyond medicinal products, Jumpcan also manufactures oral and skin care items. The company's Chinese medicine-based health products are designed to provide benefits like fatigue reduction, anti-aging effects, antioxidant support, and immune system boosting. Headquartered in Taixing, China, the company adopted its current name, Hubei Jumpcan Pharmaceutical Co., Ltd., in March 2015, having previously operated as Hubei Hongcheng General Machinery Co., Ltd.
주가
$3.87
시가총액
$3.57B
변동 (1일)
-1.64%
변동 (1년)
9.08%
국가
CN
거래 Hubei Jumpcan Pharmaceutical Co., Ltd. (600566)
카테고리
Healthcare
Hubei Jumpcan Pharmaceutical Co., Ltd. (600566)의 매출
Oct 2026 기준 매출 TTM: 0
Hubei Jumpcan Pharmaceutical Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Hubei Jumpcan Pharmaceutical Co., Ltd.의 수익 기록 (2001 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2025 | $888.83M | -19.07% |
| 2024 | $1.10B | -19.47% |
| 2023 | $1.36B | 4.58% |
| 2022 | $1.30B | 8.64% |
| 2021 | $1.20B | 27.21% |
| 2020 | $943.71M | -5.31% |
| 2019 | $996.65M | -4.89% |
| 2018 | $1.05B | 20.84% |
| 2017 | $867.17M | 28.71% |
| 2016 | $673.77M | 16.12% |
| 2015 | $580.22M | 20.34% |
| 2014 | $482.15M | 19.49% |
| 2013 | $403.51M | 31.04% |
| 2012 | $307.92M | 707.24% |
| 2011 | $38.14M | 6.17% |
| 2010 | $35.93M | 10.48% |
| 2009 | $32.52M | 4.19% |
| 2008 | $31.21M | 4.28% |
| 2007 | $29.93M | 16.41% |
| 2006 | $25.71M | 17.82% |
| 2005 | $21.82M | 23.58% |
| 2004 | $17.66M | 28.84% |
| 2003 | $13.71M | 5.73% |
| 2002 | $12.96M | -5.87% |
| 2001 | $13.77M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | - |
IN
|
